Abbott Laboratories (ABT) Moat Analysis

Established Pharmaceutical Products

Branded generic pharmaceuticals and biosimilars in emerging markets

Q2 2026 net sales were $1.499B, or 11.9082% of $12.588B in reportable-segment sales. Sales grew 8.4% reported and 8.7% comparable, but growth and a stated brand-building strategy do not establish demonstrated brand preference, retention or premium economics. The prior brand moat is therefore removed.

Pediatric Nutrition

Infant formula and pediatric nutrition products

Q2 2026 net sales were $1.025B, or 8.1427% of reportable-segment sales, down from $1.054B a year earlier. Abbott's current 2025 10-K does not repeat the old 42-state WIC disclosure cited by the prior record, and the record had no current contract-award evidence. Periodically rebid government contracts and generic marketing language do not establish a durable company-specific moat, so both prior moat claims are removed.

Adult Nutrition

Adult nutritional supplements and medical nutrition

Q2 2026 net sales were $1.119B, or 8.8894% of reportable-segment sales, down from $1.158B a year earlier. The prior evidence described category competitive factors rather than Abbott-specific preference or superior retention, so the brand moat is removed.

Core Laboratory Diagnostics

Core laboratory immunoassay, chemistry, hematology and transfusion systems and assays

Q2 2026 net sales were $1.418B, or 11.2647% of reportable-segment sales, up from $1.358B. The prior separate workflow-lock-in moat is removed because its evidence overlapped the same instrument-and-assay replacement friction already captured here.

Rapid and Molecular Diagnostics

Rapid, molecular and point-of-care infectious-disease and cardiometabolic testing

Q2 2026 net sales were $755M, or 5.9978% of reportable-segment sales, down from $815M. Abbott combined Rapid Diagnostics, Molecular Diagnostics and Point of Care into this category in 2026. The filing attributes H1 weakness to respiratory-test demand; no current category-specific evidence supports carrying the Core Laboratory installed-base moat across this heterogeneous portfolio.

Cancer Diagnostics

Colorectal cancer screening and precision-oncology diagnostic testing

Q2 2026 net sales were $919M, or 7.3006% of reportable-segment sales; comparable sales grew 13.3%, driven by Cologuard and a growing base of new and repeat users. Abbott acquired Exact Sciences on 2026-03-23 and now reports it as Cancer Diagnostics. Acquisition size, guideline inclusion, growth and repeat testing do not alone prove durable switching costs, exclusivity or a network effect, so no moat is assigned without asset-specific retention or protection evidence.

Diabetes Care (CGM and glucose monitoring)

Continuous glucose monitoring systems

Q2 2026 net sales were $2.188B, or 17.3816% of reportable-segment sales, up from $1.981B. CGM sales grew 11.0% reported and 9.5% comparable. The prior estimated operating-profit allocation is removed because Abbott discloses profit only for Medical Devices as a whole.

Cardiovascular and Electrophysiology Devices

Rhythm management, electrophysiology, heart failure, vascular and structural-heart devices

Q2 2026 combined net sales were $3.405B, or 27.0496% of reportable-segment sales: Rhythm Management $743M, Electrophysiology $861M, Heart Failure $401M, Vascular $803M and Structural Heart $597M. Abbott moved Amulet from Structural Heart to Electrophysiology on 2026-01-01. Selling to hospitals, service competition and a portfolio-wide patent estate do not demonstrate a company-specific training moat or an asset-specific IP choke point; Abbott itself says no single patent is material to the business as a whole. Both prior moat claims are removed.

Neuromodulation Devices

Implantable neuromodulation devices for chronic pain and movement disorders

Q2 2026 net sales were $260M, or 2.0654% of reportable-segment sales after assigning the six-decimal rounding residual, up from $254M. The prior record inferred training-related switching costs from the therapy type and sales channel without evidence of Abbott-specific training investment, retention or displacement difficulty, so that moat is removed.